Abstract
Background
Cardiovascular disease (CVD) is one of the major cause of mortality in diabetic patients. Evidence suggests that hyperglycemia in diabetic patients contributes to increased risk of CVD. This study is to investigate the therapeutic effects of melatonin on glucose-treated human umbilical vein endothelial cells (HUVEC) and provide insights on the underlying mechanisms.
Materials and methods
Cell viability was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Reactive oxygen species (ROS) and membrane potential was detected using 2′,7′-dichlorofluorescein diacetate and 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolcarbocyanine iodide (JC-1) dye staining, respectively. While, cell apoptosis was determined by Annexin-V staining and protein expression was measured using Western blot.
Results
Our results suggested that melatonin inhibited glucose-induced ROS elevation, mitochondria dysfunction and apoptosis on HUVEC. Melatonin inhibited glucose-induced HUVEC apoptosis via PI3K/Akt signaling pathway. Activation of Akt further activated BcL-2 pathway through upregulation of Mcl-1 expression and downregulation Bax expression in order to inhibit glucose-induced HUVEC apoptosis. Besides that, melatonin promoted downregulation of oxLDL/LOX-1 in order to inhibit glucose-induced HUVEC apoptosis.
Conclusions
In conclusion, our results suggested that melatonin exerted vasculoprotective effects against glucose-induced apoptosis in HUVEC through PI3K/Akt, Bcl-2 and oxLDL/LOX-1 signaling pathways.
Funding source: International Medical University
Research funding: The research funding was supported by International Medical University; the Grant Number is IMU 267/2013.
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: The authors have no conflicts of interest to disclose.
Informed consent: Informed consent was obtained from all individuals included in this study.
Ethical approval: Not applicable.
References
1. Einarson, TR, Acs, A, Ludwig, C, Panton, UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018;17:83–102. https://doi.org/10.1100/2012/498489.Search in Google Scholar PubMed PubMed Central
2. Lee, SI, Patel, M, Jones, CM, Narendran, P. Cardiovascular disease and type 1 diabetes: prevalence, prediction and management in an ageing population. Ther Adv Chronic Dis 2015;6:347–74. https://doi.org/10.1177/2040622315598502.Search in Google Scholar PubMed PubMed Central
3. Beckman, JA, Paneni, F, Cosentino, F, Creager, MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J 2013;34:2444–52. https://doi.org/10.1161/01.CIR.0000089189.70578.E2.Search in Google Scholar PubMed
4. Van de Oever, IM, Raterman, HG, Nurmohamed, MT, Simsek, S. Endothelial dysfunction, inflammation and apoptosis in diabetes mellitus. Mediator Inflamm 2010;2010:792393. https://doi.org/10.1155/2010/792393.Search in Google Scholar PubMed PubMed Central
5. Chait, A, Bornfeldt, KE. Diabetes and atherosclerosis: is there a role for hyperglycemia? J Lipids Res 2009;50:S335–9. https://doi.org/10.1194/jlr.R800059-JLR200.Search in Google Scholar PubMed PubMed Central
6. Giacco, F, Brownlee, M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058–70. https://doi.org/10.1161/CIRCRESAHA.110.223545.Search in Google Scholar PubMed PubMed Central
7. Calcutt, NA, Cooper, ME, Kern, TS, Schmidt, AM. Therapies for hyperglycemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov 2009;8:417–29. https://doi.org/10.1038/nrd2476.Search in Google Scholar PubMed PubMed Central
8. Brown, DI, Griendling, KK. Regulation of signal transduction by reactive oxygen species in the cardiovascular system. Circ Res 2015;116:531–49. https://doi.org/10.1161/circresaha.116.303584.Search in Google Scholar PubMed PubMed Central
9. Peluso, I, Morabito, G, Urban, L. Ioannone, F, Serafini, M. Oxidative stress in atherosclerosis development: the central role of LDL and oxidative burst. Endorc Metab Immune Disord Drug Targets 2010;12:351–60. https://doi.org/10.2174/187153012803832602.Search in Google Scholar PubMed
10. Badimon, L, Vilahur, G. LDL-cholesterol versus HDL-cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos. Ann N Y Acad Sci 2012;1254:18–32. https://doi.org/10.1111/j.1749-6632.2012.06480.x.Search in Google Scholar PubMed
11. Chen, C, Khismatullin, DB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells, PLoS One 2015;10:e0123088. https://doi.org/10.1371/journal.pone.0123088.Search in Google Scholar PubMed PubMed Central
12. Di Pietro, N, Formoso, G, Pandolfi, A. Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis. Vascul Pharmacol 2016;84:1–7. https://doi.org/10.1016/j.vph.2016.05.013.Search in Google Scholar PubMed
13. Pirillo, A, Norata, GD, Catapano, AL. LOX-1, oxLDL, and atherosclerosis, Mediators Inflamm 2013;2013:152786. https://doi.org/10.1155/2013/152786.Search in Google Scholar PubMed PubMed Central
14. Li, L, Renier, G. The oral anti-cancer agent, gliclazide, inhibit oxidized LDL-mediated LOX-1 expression, metalloproteinase-9 secretion and apoptosis in human aortic endothelial cells. Atherosclerosis 2009;204:40–6. https://doi.org/10.1016/j.atherosclerosis.2008.08.008.Search in Google Scholar PubMed
15. Antoniades, C. Oxidative stress in the vascular wall: a useful physiological process or a therapeutic target in vascular disease? Recent Pat Cardiovas Drug Discov 2011;6:74–7. https://doi.org/10.2174/157489011795933828.Search in Google Scholar PubMed
16. Sharma, S, Singh, H, Ahmad, N, Mishra, P, Tiwari, A. The role of melatonin in diabetes: therapeutic implications, Arch Endocrinol Metab 2015;59:391–9. https://doi.org/10.1590/2359-3997000000098.Search in Google Scholar PubMed
17. Winiarska, K, Fraczyk, T, Malinska, D, Drozak, J, Bryla, L. Melatonin attenuates diabetes-induces oxidative stress in rabbits. J Pineal Res 2006;40:168–76. https://doi.org/10.1111/j.1600-079X.2005.00295.x.Search in Google Scholar PubMed
18. Espino, J, Pariente, JA, Rodríguez, AB. Role of melatonin on diabetes-related metabolic disorders. World J Diabetes 2011;2:82–91. https://doi.org/10.4239/wjd.v2.i6.82.Search in Google Scholar PubMed PubMed Central
19. Gürpınar, T, Ekerbiçer, N, Uysal, N, Barut, T, Tarakç, F, Tuglu, M. The effects of the melatonin treatment on the oxidative stress and apoptosis in diabetic eye and brain. Sci World J 2012;2012:498489. https://doi.org/10.1100/2012/498489.Search in Google Scholar PubMed PubMed Central
20. Reiter, RJ, Tan, DX, Paredes, SD, Fuentes-Broto, L. Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010;42:276–85. https://doi.org/10.3109/07853890903485748.Search in Google Scholar PubMed
21. Sun, H, Gusdon, AM, Qu, S. Effects of melatonin in cardiovascular disease: progress in the past year. Curr Opin Lipidol 2016;27:408–13. https://doi.org/10.1097/MOL.0000000000000314.Search in Google Scholar PubMed PubMed Central
22. Luo, Y, Xu, W, Li, G, Cui, W. Weighing in on mTOR Complex 2 signaling: the expanding role in cell metabolism. Oxid Med Cell Longev 2018;2018:7838647. https://doi.org/10.1155/2018/7838647.Search in Google Scholar PubMed PubMed Central
23. Hemmings, BA, Restuccia, DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol 2012;4:a011189. https://doi.org/10.1101/cshperspect.a011189.Search in Google Scholar PubMed PubMed Central
24. Li, D, Mehta, JL. Upregulation of endothelial receptor for oxidized LDL (LOX-1) by oxidized LDL and implications in apoptosis of human coronary artery endothelial cells: evidence from use of antisense LOX-1 mRNA and chemical inhibitors. Arterioscler Thromb Vasc Biol 2000;20:1116–22. https://doi.org/10.1161/01.ATV.20.4.1116.Search in Google Scholar PubMed
25. Funk, SDJr. Yurdagul, A, Orr, AW. Hyperglycemia and endothelial dysfunction in atherosclerosis: lessons from type 1 diabetes. Int J Vasc Med 2018;2012:56965425. https://doi.org/10.1155/2012/569654.Search in Google Scholar PubMed PubMed Central
26. Daehn, IS. Glomerular endothelial cell stress and cross-talk with podocytes in early diabetic kidney disease. Front Med 2018;5:76. https://doi.org/10.3389/fmed.2018.00076.Search in Google Scholar PubMed PubMed Central
27. Cheng, H, Harris, RC. Renal endothelial dysfunction in diabetic nephropathy. Cardiovasc Hematol Disord Drug Targets 2014;14:22–33. https://doi.org/10.2174/1871529x14666140401110841.Search in Google Scholar PubMed PubMed Central
28. Li, Q, Lin, Y, Wang, S, Zhang, L, Go, L. GLP-1 inhibits high glucose-induced oxidative injury of vascular endothelial cells. Sci Rep 2017;7:8008–17. https://doi.org/10.1038/s41598-017-06712-z.Search in Google Scholar PubMed PubMed Central
29. Czabotar, PE, Lessene, G, Strasser, A, Adams, JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2014;15:49–63. https://doi.org/10.1038/nrm3722.Search in Google Scholar PubMed
30. Hinds, MG, Day, CL. Regulation of apoptosis: uncovering the binding determinants. Curr Opin Struct Biol 2005;15:690–9. https://doi.org/10.1016/j.sbi.2005.10.003.Search in Google Scholar PubMed
31. Lowes, DA, Webster, NR, Murphy, MP, Galley, HF. Antioxidants that protect mitochondria reduce interleukin-6 and oxidative stress, improve mitochondrial function, and reduce biochemical markers of organ dysfunction in a rat model of acute sepsis. Br J Anaesth 2013;110:472–80. https://doi.org/10.1093/bja/aes577.Search in Google Scholar
32. Túnez, I, Muñoz, MC, Medina, FJ, Salcedo, M, Feijóo, M, Montilla, P. Comparison of melatonin, vitamin E and L-carnitine in the treatment of neuro- and hepatotoxicity induced by thioacetamide. Cell Biochem Funct 2007;25:119–27. https://doi.org/10.1002/cbf.1276.Search in Google Scholar
33. Ramis, MR, Esteban, S, Miralles, A, Tan, DX, Reiter, RJ. Protective effects of melatonin and mitochondria-targeted antioxidants against oxidative stress: a review. Curr Med Chem 2015;22:2690–711. https://doi.org/10.2174/0929867322666150619104143.Search in Google Scholar
34. Hardelang, R, Pandi-Perumal, SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastroinstestinal factor, drug and prodrug. Nutr Metab 2005;2:22. https://doi.org/10.1186/1743-7075-2-22.Search in Google Scholar
35. Luo, J, Manning, BD, Cantley, LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 2003;4:257–62. https://doi.org/10.1016/s1535-6108(03)00248-4.Search in Google Scholar
36. Porta, C, Figlin, RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 2009;182:2569–77. https://doi.org/10.1016/j.juro.2009.08.085.Search in Google Scholar PubMed
37. Manning, BD, Cantley, LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–74. https://doi.org/10.1016/j.cell.2007.06.009.Search in Google Scholar PubMed PubMed Central
38. Jason, SL, Wei, C. Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signaling in pluripotency and cell fate determination. Development 2016;143:3050–60. https://doi.org/10.1242/dev.137075.Search in Google Scholar PubMed
39. Perciavalle, RM, Stewart, DP, Koss, B, Lynch, J, Milasta, S, Bathina, M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol 2012;14:575–83. https://doi.org/10.1038/ncb2488.Search in Google Scholar PubMed PubMed Central
40. Hockings, C, Asop, AE, Fennell, SC, Lee, EF, Fairlie, WD, Dewson, G, et al. Mcl-1 and Bcl-xL sequestration of Bak confers differential resistance to BH3-only proteins. Cell Death Differ 2018;25:719–32. https://doi.org/10.1038/s41418-017-0010-6.Search in Google Scholar PubMed PubMed Central
41. Chait, A, Han, CY, Oram, JF, Heinecke, JW. Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 2005;46:389–403. https://doi.org/10.1194/jlr.R400017-JLR200.Search in Google Scholar PubMed
42. Kattoor, AJ, Goel, A, Mehta, JL. LOX-1: regulation, signaling and its role in atherosclerosis. Antioxidants (Basel) 2019;2019:8. https://doi.org/10.3390/antiox8070218.Search in Google Scholar PubMed PubMed Central
43. Ganjifrockwala, F, Joseph, J, George, G. Serum oxidized LDL levels in type 2 diabetic patients with retinopathy in Mthatha region of the Eastern Cape Province of South Africa. Oxid Med Cell Longev 2016;2016:2063103. https://doi.org/10.1155/2016/2063103.Search in Google Scholar PubMed PubMed Central
44. Ghaneei, A, Yassini, S, Ghanei, ME, Shojaoddiny-Ardekani, A. Increased serum oxidized low-density lipoprotein levels in pregnancies complicated by gestational diabetes mellitus. Iran J Reprod Med 2015;13:421–4.Search in Google Scholar
45. Nakhjavani, M, Khalilzadeh, O, Khajeali, L, Esteghamati, A, Morteza, A, Jamal, A, et al. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. Lipids 2010;45:321–7. https://doi.org/10.1007/s11745-010-3401-8.Search in Google Scholar PubMed
46. Rafieian-Kopaei, M, Setorki, M, Doudi, M, Baradaran, A, Nasri, H. Atherosclerosis: process, indicators, risk factors and new hopes. Int J Prev Med 2014;5:927–46.Search in Google Scholar
47. Hansson, GK, Robertson, AK, Soderberg-Naucler, C. Inflammation and atherosclerosis. Ann Rev of Pathol 2006;1:297–329. https://doi.org/10.1161/hc0902.104353.Search in Google Scholar PubMed
48. Ogura, S, Kakino, A, Sato, Y, Fujita, Y, Iwamoto, S, Otsui, K, et al. LOX-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J 2009;73:1993–9. https://doi.org/10.1253/circj.cj-09-0587.Search in Google Scholar PubMed
49. Rudijanto, A. The expression and downstream effect of lectin like-oxidized low-density lipoprotein 1 (LOX-1) in hyperglycemic state. Acta Med Indones 2007;39:36–43.Search in Google Scholar
50. Li, L, Sawamura, T, Ranier, G. Glucose enhances endothelial LOX-1 expression. Role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. Diabetes 2003;52:1843–50. https://doi.org/10.2337/diabetes.52.7.1843.Search in Google Scholar PubMed
51. Pothineni, NVK, Karathanasis, SK, Ding, Z, Arulandu, A, Varughese, KI, Mehta, JL. LOX-1 in atherosclerosis and myocardial ischemia: biology, genetics, and modulation. J Am Coll Cardiol 2017;69:2759–68. https://doi.org/10.1016/j.jacc.2017.04.010.Search in Google Scholar PubMed
52. Xu, S, Ogura, S, Chen, J, Little, PJ, Moss, J, Liu, P. LOX-1 in atherosclerosis: biological functions and pharmacological modifiers. Cell Mol Life Sci 2013;70:2859–72. https://doi.org/10.1007/s00018-012-1194-z.Search in Google Scholar PubMed PubMed Central
53. Yoshimoto, R, Fujita, Y, Kakino, A, Iwamoto, S, Takaya, T, Sawamura, T. The discovery of LOX-1, its ligands and clinical significance. Cardiovasc Drugs Ther 2011;25:379–91. https://doi.org/10.1007/s10557-011-6324-6.Search in Google Scholar PubMed PubMed Central
54. Wakatsuki, A, Okatani, Y, Ikenoune, N, Izumiya, C, Kaneda, C. Melatonin inhibit oxidative modification of low-density lipoprotein particles in normalipidemic post-menopausal women. J Pineal Res 2000;28:136–42. https://doi.org/10.1034/j.1600-079X.2001.280302.x.Search in Google Scholar
55. Kelly, MR, Loo, G. Melatonin inhibits oxidative modification of human low-density lipoprotein. J Pineal Res 1997;22:203–9. https://doi.org/10.1111/j.1600-079X.1997.tb00323.x.Search in Google Scholar
56. Zhu, HQ, Cheng, XW, Xiao, LL, Jiang, ZK, Zhou, Q, Gui, SY, et al. Melatonin prevents oxidized low-density lipoprotein-induced increase of myosin light chain kinase activation and expression in HUVEC through ERK/MAPK signal transduction. J Pineal Res 2008;45:328–34. https://doi.org/10.1111/j.1600-079X.2008.00595.x.Search in Google Scholar PubMed
57. Seegar, H, Mueck, AO, Lippert, TH. Effect of melatonin and metabolites on copper-mediated oxidation of flow density lipoprotein. Br J Clin Pharmacol 1997;44:283–4. https://doi.org/10.1046/j.1365-2125.1997.00648.x.Search in Google Scholar PubMed PubMed Central
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Letter to the Editor
- Evidence-based medicine is a valuable tool for a successful decision-making on risk-reducing bilateral mastectomy
- Original Articles
- Melatonin inhibits high glucose-induced ox-LDL/LDL expression and apoptosis in human umbilical endothelial cells
- Effects of metformin and insulin therapy regimens on postpartum oral glucose tolerance test results in pregnant women with gestational diabetes mellitus: a comparative study
- Association of IL-33 gene rs16924159 polymorphism and recurrent pregnancy loss in Iranian Azeri women
- Greater effects of high- compared with moderate-intensity interval training on thyroid hormones in overweight/obese adolescent girls
- Effect of Artemisia absinthium ethanolic extract on oxidative stress markers and the TLR4, S100A4, Bax and Bcl-2 genes expression in the kidney of STZ-induced diabetic rats
- Associations of endothelial biomarkers, nitric oxide metabolites and endothelin, with blood pressure and coronary lesions depend on cardiovascular risk and sex to mark endothelial dysfunction on the SCORE scale
- Association of nitric oxide synthase 3 gene rs1799983 G/T polymorphism with idiopathic asthenozoospermia in Iranian Azeri males: a case-control study
- Adiponectin and leptin levels in normal weight women with polycystic ovary syndrome
- Review Articles
- Association between vitamin D deficiency and prevalence of metabolic syndrome in female population: a systematic review
- Vitamin D and sleep duration: Is there a bidirectional relationship?
- Challenges of post-traumatic stress disorder (PTSD) in Iraq: biochemical network and methodologies. A brief review
- Female urine incontinence: vaginal erbium laser (VEL) effectiveness and safety
- Breast cancer risk factors in Iran: a systematic review & meta-analysis
- Effects of melatonin supplementation on oxidative stress: a systematic review and meta-analysis of randomized controlled trials
Articles in the same Issue
- Letter to the Editor
- Evidence-based medicine is a valuable tool for a successful decision-making on risk-reducing bilateral mastectomy
- Original Articles
- Melatonin inhibits high glucose-induced ox-LDL/LDL expression and apoptosis in human umbilical endothelial cells
- Effects of metformin and insulin therapy regimens on postpartum oral glucose tolerance test results in pregnant women with gestational diabetes mellitus: a comparative study
- Association of IL-33 gene rs16924159 polymorphism and recurrent pregnancy loss in Iranian Azeri women
- Greater effects of high- compared with moderate-intensity interval training on thyroid hormones in overweight/obese adolescent girls
- Effect of Artemisia absinthium ethanolic extract on oxidative stress markers and the TLR4, S100A4, Bax and Bcl-2 genes expression in the kidney of STZ-induced diabetic rats
- Associations of endothelial biomarkers, nitric oxide metabolites and endothelin, with blood pressure and coronary lesions depend on cardiovascular risk and sex to mark endothelial dysfunction on the SCORE scale
- Association of nitric oxide synthase 3 gene rs1799983 G/T polymorphism with idiopathic asthenozoospermia in Iranian Azeri males: a case-control study
- Adiponectin and leptin levels in normal weight women with polycystic ovary syndrome
- Review Articles
- Association between vitamin D deficiency and prevalence of metabolic syndrome in female population: a systematic review
- Vitamin D and sleep duration: Is there a bidirectional relationship?
- Challenges of post-traumatic stress disorder (PTSD) in Iraq: biochemical network and methodologies. A brief review
- Female urine incontinence: vaginal erbium laser (VEL) effectiveness and safety
- Breast cancer risk factors in Iran: a systematic review & meta-analysis
- Effects of melatonin supplementation on oxidative stress: a systematic review and meta-analysis of randomized controlled trials